drugset / Trial / NCT06828341
A Single-arm, Open, Exploratory Clinical Study of Allogeneic CAR-T Cells in the Treatment of Relapsed/Refractory Brain Gliomas With Positive CD70 Expression
Phase 0
Unknown
3 enrolled
JIANG LONGWEI
Nanjing Kanghe Cell Gene Engineering Research Institute Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
The goal of this clinical trial is to learn if allogeneic CAR-T cells can treat patients with advanced gliomas. The main questions it aims to answer are: Evaluate the safety of allogeneic CAR-T cells in the treatment of advanced gliomas. To evaluate the effectiveness of allogeneic CAR-T cells in the treatment of advanced gliomas and to study its immunological properties in patients.
Timeline
- Start
- 2024-06-13
- Primary completion
- 2024-07-06
- Completion
- 2026-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CAR-T | Cell therapy | 1e+06 cells/kg | Intrathecal |